Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):431-440.e13. doi: 10.1016/j.clml.2019.03.015. Epub 2019 Mar 26.

PMID:
31056348
2.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.

Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.

PMID:
30926081
3.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E.

Blood Adv. 2019 Feb 26;3(4):508-518. doi: 10.1182/bloodadvances.2018027409.

4.

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.

Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H.

Exp Hematol Oncol. 2019 Jan 3;8:1. doi: 10.1186/s40164-018-0125-6. eCollection 2019.

5.

How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.

Odenike O.

Blood. 2018 Nov 29;132(22):2339-2350. doi: 10.1182/blood-2018-03-785907. Epub 2018 Oct 17. Review.

PMID:
30333119
6.

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA.

Cancer. 2018 Dec 15;124(24):4601-4609. doi: 10.1002/cncr.31769. Epub 2018 Oct 5.

PMID:
30289970
7.

Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.

D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS.

Leuk Lymphoma. 2019 Mar;60(3):629-638. doi: 10.1080/10428194.2018.1493728. Epub 2018 Aug 2.

PMID:
30070150
8.

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W.

Exp Hematol Oncol. 2018 Jan 11;7:1. doi: 10.1186/s40164-018-0093-x. eCollection 2018.

9.

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.

Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu H.

J Hematol Oncol. 2018 Jan 5;11(1):4. doi: 10.1186/s13045-017-0550-8.

10.

Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.

Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS.

Biol Blood Marrow Transplant. 2018 May;24(5):997-1004. doi: 10.1016/j.bbmt.2017.12.794. Epub 2017 Dec 27.

11.

Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.

Odenike O.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):460-469. doi: 10.1182/asheducation-2017.1.460. Review.

12.

Novel Therapies for Myelofibrosis.

Pettit K, Odenike O.

Curr Hematol Malig Rep. 2017 Dec;12(6):611-624. doi: 10.1007/s11899-017-0403-0. Review.

13.

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP.

J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.

14.

Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.

Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W.

Leuk Lymphoma. 2017 Sep;58(9):1-7. doi: 10.1080/10428194.2017.1289524. Epub 2017 Feb 20.

PMID:
28278716
15.

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.

Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ.

J Hematol Oncol. 2016 Dec 8;9(1):137.

16.

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.

Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA.

Leukemia. 2017 Feb;31(2):393-402. doi: 10.1038/leu.2016.215. Epub 2016 Aug 1.

17.

Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.

Pettit K, Odenike O.

Expert Rev Hematol. 2016 Jul 29:1-9. [Epub ahead of print]

PMID:
27385032
18.

Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1065-1072. doi: 10.1016/j.bbmt.2016.02.010. Epub 2016 Feb 19.

19.

Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.

van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A.

Haematologica. 2016 May;101(5):634-43. doi: 10.3324/haematol.2015.138594. Epub 2016 Feb 11.

20.

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.

Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, Wang X, Brail L, Borthakur G.

Leuk Lymphoma. 2016 Aug;57(8):1800-6. doi: 10.3109/10428194.2015.1122781. Epub 2016 Jan 6.

PMID:
26735141
21.

Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.

D'Angelo CR, Kocherginsky M, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz AS.

Leuk Lymphoma. 2016 Aug;57(8):1807-13. doi: 10.3109/10428194.2015.1113279. Epub 2015 Dec 24.

PMID:
26699199
22.

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies.

Pettit K, Odenike O.

Front Oncol. 2015 Dec 14;5:280. doi: 10.3389/fonc.2015.00280. eCollection 2015. Review.

23.

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.

Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y.

Oncotarget. 2015 Oct 20;6(32):33410-25. doi: 10.18632/oncotarget.5418.

24.

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Röth A, Daskalakis M, Burington B, Stuart M, Snyder DS.

N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479.

25.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.

27.

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.

Tallarico M, Odenike O.

Curr Hematol Malig Rep. 2015 Jun;10(2):112-7. doi: 10.1007/s11899-015-0259-0. Review.

PMID:
25893311
28.

Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R.

Bone Marrow Transplant. 2015 May;50(5):628-36. doi: 10.1038/bmt.2014.323. Epub 2015 Feb 9. Review.

29.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.

J Clin Oncol. 2015 Mar 1;33(7):786-809. doi: 10.1200/JCO.2014.59.9746. Epub 2015 Jan 20. Review. No abstract available.

PMID:
25605863
30.

A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.

Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W.

Invest New Drugs. 2015 Apr;33(2):371-9. doi: 10.1007/s10637-014-0194-2. Epub 2014 Dec 9.

31.

Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Yacoub A, Odenike O, Verstovsek S.

Curr Hematol Malig Rep. 2014 Dec;9(4):350-9. doi: 10.1007/s11899-014-0229-y. Review.

32.

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.

Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS.

Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. Epub 2014 May 9.

33.

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF.

Blood. 2014 Jun 5;123(23):3574-7. doi: 10.1182/blood-2014-02-555607. Epub 2014 Mar 31.

34.

Beyond JAK inhibitor therapy in myelofibrosis.

Odenike O.

Hematology Am Soc Hematol Educ Program. 2013;2013:545-52. doi: 10.1182/asheducation-2013.1.545. Review.

PMID:
24319230
35.

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.

Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S.

J Hematol Oncol. 2013 Oct 29;6(1):81. doi: 10.1186/1756-8722-6-81.

36.

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O.

Clin Cancer Res. 2014 Jan 15;20(2):490-8. doi: 10.1158/1078-0432.CCR-13-1311. Epub 2013 Oct 31.

37.

A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.

Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W.

Bone Marrow Transplant. 2013 Nov;48(11):1437-43. doi: 10.1038/bmt.2013.79. Epub 2013 Jun 17.

38.

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology.

Invest New Drugs. 2013 Oct;31(5):1311-20. doi: 10.1007/s10637-013-9978-z. Epub 2013 May 23.

39.

Age-related differences in disease characteristics and clinical outcomes in polycythemia vera.

Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR.

Leuk Lymphoma. 2013 Sep;54(9):1989-95. doi: 10.3109/10428194.2012.759656. Epub 2013 Jan 8.

PMID:
23245211
40.

A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.

Hossain NM, Jain N, Steinmetz JL, McConville JF, Anastasi J, Odenike O.

Chest. 2012 Dec;142(6):1680-1683. doi: 10.1378/chest.12-0652. No abstract available.

PMID:
23208343
41.

Immune reconstitution after combined haploidentical and umbilical cord blood transplant.

Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K.

Leuk Lymphoma. 2013 Jun;54(6):1242-9. doi: 10.3109/10428194.2012.739688. Epub 2013 Mar 1.

PMID:
23088744
42.

Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.

Jamieson K, Odenike O.

Expert Opin Pharmacother. 2012 Oct;13(15):2171-87. doi: 10.1517/14656566.2012.724061. Epub 2012 Sep 13. Review.

PMID:
22971003
43.

Influence of related donor age on outcomes after peripheral blood stem cell transplantation.

Richa EM, Kunnavakkam R, Godley LA, Kline J, Odenike O, Larson RA, Nguyen V, Stock W, Wickrema A, Van Besien K, Artz AS.

Cytotherapy. 2012 Jul;14(6):707-15. doi: 10.3109/14653249.2012.681041. Epub 2012 May 2.

PMID:
22548695
44.

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.

Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S.

Leuk Lymphoma. 2012 Nov;53(11):2136-42. doi: 10.3109/10428194.2012.681655. Epub 2012 Jun 12.

45.

Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.

Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A.

Am J Hematol. 2012 May;87(5):562-8. doi: 10.1002/ajh.23169. Epub 2012 Mar 28.

46.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

PMID:
22147736
47.

Myelodysplastic syndromes.

Odenike O, Anastasi J, Le Beau MM.

Clin Lab Med. 2011 Dec;31(4):763-84. doi: 10.1016/j.cll.2011.08.005. Epub 2011 Oct 10. Review.

48.

Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.

van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS.

Biol Blood Marrow Transplant. 2012 Jun;18(6):913-21. doi: 10.1016/j.bbmt.2011.10.041. Epub 2011 Nov 9.

49.

Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.

Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, Kline J, Nguyen V, Cunningham J, Larson RA, del Cerro P, Schroeder L, Pape L, Stock W, Wickrema A, Artz AS, van Besien K.

Blood. 2011 Dec 8;118(24):6438-45. doi: 10.1182/blood-2011-08-372508. Epub 2011 Oct 5.

50.

High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).

Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W.

Leuk Lymphoma. 2012 Mar;53(3):445-50. doi: 10.3109/10428194.2011.621562.

PMID:
21913806

Supplemental Content

Loading ...
Support Center